AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
Log in

CVE:HLSHLS Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume49,300 shs
Average Volume97,793 shs
Market CapitalizationC$384.86 million
P/E RatioN/A
Dividend Yield1.46%
BetaN/A
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company was incorporated in 2014 and is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone647-495-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$65.13 million
Book ValueC$6.11 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$384.86 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HLS News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

HLS Therapeutics (CVE:HLS) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of HLS Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for HLS Therapeutics.

Has HLS Therapeutics been receiving favorable news coverage?

Headlines about HLS stock have been trending somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. HLS Therapeutics earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about HLS Therapeutics.

Who are some of HLS Therapeutics' key competitors?

What other stocks do shareholders of HLS Therapeutics own?

Who are HLS Therapeutics' key executives?

HLS Therapeutics' management team includes the following people:
  • Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 57)
  • Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder, CEO & Director (Age 61)
  • Mr. Gilbert Godin, Pres & COO (Age 59)
  • Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 47)
  • Mr. Joseph Anthony MacLean B. Com., LL.B, Director of Corp. Devel. (Age 50)

What is HLS Therapeutics' stock symbol?

HLS Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HLS."

How big of a company is HLS Therapeutics?

HLS Therapeutics has a market capitalization of C$0.00 and generates C$65.13 million in revenue each year.

What is HLS Therapeutics' official website?

The official website for HLS Therapeutics is www.hlstherapeutics.com.

How can I contact HLS Therapeutics?

The company can be reached via phone at 647-495-9000.

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.